A

    ANEB (ANEB)

    Official site

    BIOTECHNOLOGY

    $0.32
    -0.02 (-4.55%)

    Last updated: Aug 28, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(11/20)
    Avg Surprise
    -335.24%
    Streak
    4 Q

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-0.14
    Range$-0.14 - $-0.14
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.14
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    Jun 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-$-0.09---
    Mar 26EST
    		-$-0.14---
    Dec 25
    		$-0.05N/A+61.54%Beat+44.3%
    Sep 25
    		$-0.05N/A+58.33%Beat+41.1%
    Jun 25
    		$-0.05$-0.05+0.00%Beat+0.0%
    Mar 25
    		$-0.04$-0.05+20.00%Beat+33.3%
    Dec 24
    		$-0.09$-0.08-12.25%Miss+18.4%
    Sep 24
    		$-0.08$-0.05-69.80%Miss+15.1%
    Jun 24
    		$-0.05N/A+61.54%Beat+50.0%
    Mar 24
    		$-0.06$-0.12+50.00%Beat+45.5%
    Dec 23
    		$-0.11$-0.10-10.00%Miss+26.7%
    Sep 23
    		$-0.10$-0.12+16.67%Beat+9.1%
    Jun 23
    		$-0.10$-0.11+9.09%Beat+0.0%
    Mar 23
    		$-0.11$-0.16+31.25%Beat-37.5%
    Dec 22
    		$-0.15$-0.11-36.36%Miss-200.0%
    Sep 22
    		$-0.11$-0.10-10.00%Miss-57.1%
    Jun 22
    		$-0.10$-0.07-42.86%Miss+93.7%
    Mar 22
    		$-0.08$-0.05-60.00%Miss+88.4%
    Dec 21
    		$-0.05$-0.06+16.67%Beat+0.0%
    Sep 21
    		$-0.07$-0.11+36.36%Beat+48.9%
    Jun 21
    		$-1.59$-0.03-5200.00%Miss-1061.4%
    Mar 21
    		$-0.69$-0.04-1625.00%Miss-
    Dec 20
    		$-0.05$0.00N/AMiss-
    Sep 20
    		$-0.14$0.00N/AMiss-
    Jun 20
    		$-0.14$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.66EV/EBITDAN/A
    Price/FCF-2.22xFCF Yield-45.13%
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-26.86x
    Current Ratio6.24xQuick Ratio6.24x
    Trading Statistics
    BetaN/AAvg Volume186
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.35
    SMA 20$0.33
    SMA 50$0.33
    SMA 200$0.82
    EMA 10$0.33
    EMA 20$0.33
    EMA 50$0.35
    EMA 200$0.75

    MACD

    Line: 0.00Signal: 0.00Hist: -0.00

    ADX

    ADX: 31.9+DI: 19.8-DI: 57.0

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down60.0
    PSAR$0.13

    Bollinger Bands

    Upper Band$0.39
    Lower Band$0.27
    %B Position3791%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    46.9

    Momentum Oscillators

    Stoch %K73.2
    Stoch %D73.6
    Williams %R-29.7
    ROC (10d)-1.6%
    Momentum-0.01
    CCI (20d)-33.0
    MFI (14d)11.0

    Volatility Measures

    ATR (14d)$0.03(10.1%)
    StdDev (20d)0.03
    Hist Vol135.6%(High)

    Volume Flow

    VWAP$0.32
    OBV14.3M
    AD Line5.1M
    CMF (20d)0.150

    Volume Metrics

    Avg Vol (20d)0.2K
    Vol Ratio0.6x
    VWMA (20d)$0.32

    Pivot Points

    R3$0.33
    R2$0.33
    R1$0.33
    Pivot Point$0.33
    S1$0.33
    S2$0.33
    S3$0.33

    Advanced Oscillators

    TSI0.57
    Ultimate Osc42.1
    KST30775.53

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0N/AN/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0N/AN/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$2.62M$2.26M$2.33M$1.89M$2.59M$2.41M$1.34M$1.66M$2.76M$2.54M$2.49M$2.86M
    R&D$1.16M$809,991$1.13M$638,324$1.22M$1.31M$467,706$748,339$1.06M$1.27M$1.42M$1.09M
    SG&A$1.46M$1.45M$1.20M$1.25M$1.37M$1.10M$872,661$915,912$1.70M$1.27M$1.08M$1.77M
    Operating Income$-2,619,910$-2,260,260$-2,330,884$-1,892,322$-2,588,151$-2,412,124$-1,340,367$-1,664,251$-2,760,459$-2,543,678$-2,494,389$-2,864,041
    Interest Income$85,410$109,616$122,583$102,257$7,067$26,006$50,218$68,084$75,522$55,198$4,439$79,152
    Interest Expense$17,439$17,439$17,439$245,182$59,696$59,697$59,696$59,696$31,838$0$767$0
    Income Before Tax$-1,999,397$-2,158,354$-2,144,828$-1,676,169$-2,463,030$-2,200,736$-1,349,969$-1,653,542$-2,717,369$-2,480,823$-2,495,156$-2,797,971
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,999,397$-2,158,354$-2,144,828$-1,676,169$-2,463,030$-2,200,736$-1,349,969$-1,653,542$-2,717,369$-2,480,823$-2,495,580$-2,797,971
    EBITDA$-2,067,368$-2,140,915$-2,232,533$-1,288,062$-2,350,705$-2,107,348$-1,280,795$-1,602,234$-2,729,215$-2,536,021$-2,499,595$-2,877,123
    EBIT$-2,067,368$-2,140,915$-2,249,972$-1,533,244$-2,410,401$-2,167,045$-1,340,491$-1,661,930$-2,761,053$-2,536,021$-2,499,595$-2,877,123
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANEB

    News

    Anebulo Pharmaceuticals, Inc. Revenue Breakdown – LS:A3CM1D

    This article provides a financial overview of Anebulo Pharmaceuticals, Inc. (A3CM1D) on TradingView, focusing on its revenue breakdown. It lists various financial data sections available, such as statements, statistics, dividends, earnings, segments, and regional performance. The content indicates that market data is provided by ICE Data Services and reference data by FactSet.

    TradingView•7/26/26•
    Neutral

    Anebulo Pharmaceuticals (ANEB) Proxy Filing Summary

    Anebulo Pharmaceuticals has filed a proxy statement outlining six key proposals for shareholder vote at its annual meeting on April 4, 2025. These proposals include board declassification, director elections, an increase in authorized common stock, and the ratification of their independent auditor. The board recommends approval of all proposals, emphasizing alignment with best governance practices and future financing flexibility.

    Quartr•7/18/26•
    Neutral

    Enterprise value to revenue forward of Anebulo Pharmaceuticals, Inc. – LSX:A3CM1D

    This article provides a brief snapshot of Anebulo Pharmaceuticals, Inc. (LSX:A3CM1D) focusing on its enterprise value to revenue forward. The content is primarily a navigation and platform interface, with minimal specific financial data directly presented, indicating it's likely a headline for a detailed financial view on a trading platform like TradingView.

    TradingView•7/8/26•
    Neutral

    Enterprise value to EBITDA forward of Anebulo Pharmaceuticals Inc – OTC:ANEB

    This article provides financial information for Anebulo Pharmaceuticals Inc, trading under the OTC:ANEB ticker. It specifically focuses on the enterprise value to EBITDA forward metric. The content was sourced from TradingView, which offers various financial analysis tools and market data.

    TradingView•7/8/26•
    Neutral

    Enterprise value to revenue forward of Anebulo Pharmaceuticals Inc – OTC:ANEB

    This article displays the "Enterprise value to revenue forward" metric for Anebulo Pharmaceuticals Inc (OTC:ANEB) on TradingView. It appears to be a data point or a financial statistic presented without further elaboration or analysis. The content is primarily a page title within a financial data platform.

    TradingView•7/8/26•
    Neutral

    Frequently Asked Questions About ANEB

    Does ANEB pay dividends?
    ANEB (ANEB) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In